Publications

Detailed Information

Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area

DC Field Value Language
dc.contributor.authorKim, Hye Won-
dc.contributor.authorPark, Jin Kyun-
dc.contributor.authorYang, Ji-Ae-
dc.contributor.authorYoon, Young Im-
dc.contributor.authorLee, Eun Young-
dc.contributor.authorSong, Yeong Wook-
dc.contributor.authorKim, Hang Rae-
dc.contributor.authorLee, Eun Bong-
dc.date.accessioned2024-05-16T01:31:58Z-
dc.date.available2024-05-16T01:31:58Z-
dc.date.created2019-10-28-
dc.date.created2019-10-28-
dc.date.created2019-10-28-
dc.date.created2019-10-28-
dc.date.issued2014-09-
dc.identifier.citationClinical Rheumatology, Vol.33 No.9, pp.1307-1312-
dc.identifier.issn0770-3198-
dc.identifier.urihttps://hdl.handle.net/10371/202636-
dc.description.abstractClinical characteristics of antitumor necrosis factor (TNF) agents-related tuberculosis (TB) in ankylosing spondylitis (AS) are not well described. The aim was to compare the incidences and the characteristics of TB in AS and rheumatoid arthritis (RA) during TNF inhibitor treatment. AS (n = 1,322) and RA (n = 3,154) patients who received medical care between January 2001 and August 2011 were enrolled. The incidence of TB in patients treated, or not, with TNF inhibitors and the clinical features associated with TB were explored. Seven patients with AS and seven with RA developed TB while receiving TNF inhibitor therapy, resulting in an incidence rate of 600.2/100,000 person-years (PYs) (95 % confidence interval (CI), 241.3-1236.3) for those with AS and 771.6/100,000 PYs (95 % CI, 310.2-1589.9) for those with RA. Incidence rate ratios for TNF inhibitor-treated vs. untreated patients were 4.87 for AS (95 % CI, 1.50-15.39; p < 0.001) and 3.61 for RA (95 % CI, 1.38-8.07; p < 0.001). Low body mass index was identified as a significant risk factor for TB in the AS group (odds ratio (OR), 13.0; p = 0.002). Extrapulmonary TB was predominant at 85.7 % during TNF inhibitor treatment. Three (42.8 %) of the AS patients, but none of the RA patients, developed TB with concomitant isoniazid. All AS patients recovered from TB whereas two of seven RA patients died. Treatment with TNF inhibitors significantly increases the risk of extrapulmonary TB in AS. Symptoms of infection should warrant clinicians to evaluate for TB during TNF inhibitor therapy in AS patients.-
dc.language영어-
dc.publisherSpringer Verlag-
dc.titleComparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area-
dc.typeArticle-
dc.identifier.doi10.1007/s10067-013-2387-z-
dc.citation.journaltitleClinical Rheumatology-
dc.identifier.wosid000340588400015-
dc.identifier.scopusid2-s2.0-84906333847-
dc.citation.endpage1312-
dc.citation.number9-
dc.citation.startpage1307-
dc.citation.volume33-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorPark, Jin Kyun-
dc.contributor.affiliatedAuthorLee, Eun Young-
dc.contributor.affiliatedAuthorSong, Yeong Wook-
dc.contributor.affiliatedAuthorKim, Hang Rae-
dc.contributor.affiliatedAuthorLee, Eun Bong-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusANTI-TNF THERAPY-
dc.subject.keywordPlusPLACEBO-CONTROLLED TRIAL-
dc.subject.keywordPlusEXTRAPULMONARY TUBERCULOSIS-
dc.subject.keywordPlusBIOLOGICS REGISTER-
dc.subject.keywordPlusBRITISH SOCIETY-
dc.subject.keywordPlusFACTOR BLOCKERS-
dc.subject.keywordPlusRISK-
dc.subject.keywordPlusINFLIXIMAB-
dc.subject.keywordPlusPATHOGENESIS-
dc.subject.keywordPlusETANERCEPT-
dc.subject.keywordAuthorAnkylosing spondylitis-
dc.subject.keywordAuthorRheumatoid arthritis-
dc.subject.keywordAuthorTNF inhibitor-
dc.subject.keywordAuthorTuberculosis-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
Research Area Function, Immune modulation by metabolites, T-cell anergy, differentiation of memory CD8+ T cells, metabolism

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share